V2H

(1S,3R,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraene-1,3-diol

Find entries where: V2H

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	(1S,3R,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraene-1,3-diol
Synonyms	1-alpha-hydroxy-vitamin D2
Identifiers	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol
Formula	C₂₈ H₄₄ O₂
Molecular Weight	412.648
Type	NON-POLYMER
Isomeric SMILES	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
InChI	InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
InChIKey	HKXBNHCUPKIYDM-CGMHZMFXSA-N

Chemical Details
Formal Charge	0
Atom Count	74
Chiral Atom Count	7
Bond Count	76
Aromatic Bond Count	0

Drug Info: DrugBank

DrugBank ID	DB06410
Name	Doxercalciferol
Groups	approved
Description	Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.
Synonyms	Doxercalciférolum 1α-Hydroxyergocalciferol Doxercalciferol 1-Hydroxyvitamin D2 (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol 1-Hydroxyergocalciferol Doxercalciferolum 1α-hydroxyvitamin D2
Brand Names	Doxercalciferol Hectorol
Indication	Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease.
Categories	Anti-Parathyroid Agents Bone Density Conservation Agents Calcium Homeostasis Cholestanes Cholestenes Diet, Food, and Nutrition Food Fused-Ring Compounds Lipids Membrane Lipids Micronutrients Physiological Phenomena Secosteroids Steroids Sterols Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins Vitamin D and Analogues Vitamins Vitamins (Fat Soluble)
ATC-Code	H05BX03
CAS number	54573-75-0

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Vitamin D3 receptor	MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRR...	unknown	suppressor
Sterol 26-hydroxylase, mitochondrial	MAALGCARLRWALRGAGRGLCPHGARAKAAIPAALPSDKATGAPGAGPGV...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682